Giuseppe Di Lorenzo

Summary

Publications

  1. doi request reprint Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Eur Urol 54:1089-94. 2008
  2. doi request reprint Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Naples, Italy
    Cancer Chemother Pharmacol 67:1455-61. 2011
  3. doi request reprint Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis
    Giuseppe Di Lorenzo
    Genitourinary Cancer Section and Rare Cancer Center, University Federico II, Naples, Italy
    BJU Int 110:E661-6. 2012
  4. doi request reprint Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Cancer 115:517-23. 2009
  5. doi request reprint Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study
    Giuseppe Di Lorenzo
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Eur Urol 60:1280-4. 2011
  6. ncbi request reprint Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience
    Marco De Sio
    Department of Urology, Second University, Naples, Italy
    J Endourol 20:12-6. 2006
  7. doi request reprint Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers
    Matteo Ferro
    Department of Urology, University of Naples Federico II, Naples, Italy
    Clin Chim Acta 413:1274-8. 2012
  8. doi request reprint Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients
    Giuseppe Di Lorenzo
    University Federico II, Naples, Italy
    Anticancer Drugs 20:277-80. 2009
  9. doi request reprint Combination of docetaxel and cetuximab for penile cancer: a case report and literature review
    Pasquale Rescigno
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Anticancer Drugs 23:573-7. 2012
  10. ncbi request reprint How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature
    Riccardo Autorino
    Urology Clinic, Second University, Department of Oncology, Federico II University, Vico Santo Spirito 54, 80132 Naples, Italy
    J Urol 174:2091-7. 2005

Collaborators

Detail Information

Publications45

  1. doi request reprint Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Eur Urol 54:1089-94. 2008
    ..No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure...
  2. doi request reprint Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
    Carlo Buonerba
    Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Naples, Italy
    Cancer Chemother Pharmacol 67:1455-61. 2011
    ..Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients...
  3. doi request reprint Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis
    Giuseppe Di Lorenzo
    Genitourinary Cancer Section and Rare Cancer Center, University Federico II, Naples, Italy
    BJU Int 110:E661-6. 2012
    ..Neutropenia was the most important grade 3-4 side effect observed, occurring in 20% of patients. These data provide confirmation that such a combination regimen is moderately effective and well tolerated in patients with SCCP...
  4. doi request reprint Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Cancer 115:517-23. 2009
    ....
  5. doi request reprint Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study
    Giuseppe Di Lorenzo
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Eur Urol 60:1280-4. 2011
    ..Previously published preliminary findings showed promising activity of paclitaxel in chemotherapy-pretreated metastatic penile cancer...
  6. ncbi request reprint Medical expulsive treatment of distal-ureteral stones using tamsulosin: a single-center experience
    Marco De Sio
    Department of Urology, Second University, Naples, Italy
    J Endourol 20:12-6. 2006
    ..To evaluate the efficacy of the addition of tamsulosin to our standard expulsive pharmacologic therapy for the treatment of distal-ureteral stones...
  7. doi request reprint Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers
    Matteo Ferro
    Department of Urology, University of Naples Federico II, Naples, Italy
    Clin Chim Acta 413:1274-8. 2012
    ..In conclusion, %p2PSA, phi and PCA3 may predict a diagnosis of PCa in men undergoing their first prostate biopsy. PCA3 score is more useful in discriminating between HGPIN and non-cancer...
  8. doi request reprint Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients
    Giuseppe Di Lorenzo
    University Federico II, Naples, Italy
    Anticancer Drugs 20:277-80. 2009
    ..Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings...
  9. doi request reprint Combination of docetaxel and cetuximab for penile cancer: a case report and literature review
    Pasquale Rescigno
    Genitourinary Oncology and Rare Cancer Center, Federico II University, Naples, Italy
    Anticancer Drugs 23:573-7. 2012
    ..Only mild mucositis and skin toxicity had been detected. Our case report, the first in the literature, shows that this combination is active and well tolerated in penile squamous cell carcinoma...
  10. ncbi request reprint How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature
    Riccardo Autorino
    Urology Clinic, Second University, Department of Oncology, Federico II University, Vico Santo Spirito 54, 80132 Naples, Italy
    J Urol 174:2091-7. 2005
    ..There is growing interest among urologists on the need for decreasing pain during transrectal ultrasound (TRUS) guided prostate biopsy...
  11. ncbi request reprint Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    World J Gastroenterol 13:6553-7. 2007
    ..To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase II study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA)...
  12. ncbi request reprint Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study
    Sisto Perdonà
    Department of Urology, National Cancer Institute, Naples, Italy
    Urology 66:1282-6. 2005
    ..To evaluate the reliability and morbidity of dynamic sentinel node biopsy compared with radical inguinal lymphadenectomy (RIL) in the treatment of selected patients with squamous cell penile carcinoma...
  13. doi request reprint A comprehensive outlook on intracerebral therapy of malignant gliomas
    Carlo Buonerba
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Crit Rev Oncol Hematol 80:54-68. 2011
    ....
  14. doi request reprint Castration-resistant prostate cancer: current and emerging treatment strategies
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Drugs 70:983-1000. 2010
    ....
  15. ncbi request reprint Hormone-refractory prostate cancer: where are we going?
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Drugs 67:1109-24. 2007
    ..Vaccine therapy offers an active immunological approach for combating malignancy in a targeted manner...
  16. ncbi request reprint Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Eur Urol 46:712-6. 2004
    ..The current study investigated the clinical benefit, the impact on biochemical and objective response and tolerability of weekly docetaxel with vinorelbine (VIN-DOX) in symptomatic patients with hormone refractory prostate cancer (HRPC)...
  17. ncbi request reprint FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Seconda Universita degli Studi, Naples, Italy
    Jpn J Clin Oncol 34:747-50. 2004
    ..We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients...
  18. ncbi request reprint Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience
    Sisto Perdonà
    Comprehensive Urology Unit, National Tumor Institute, G Pascale Foundation, Naples, Italy
    Cancer 112:75-83. 2008
    ..The authors evaluated their long-term experience with combined-modality, conservative treatment in patients with muscle-invasive bladder cancer...
  19. doi request reprint Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?
    Chiara Gallo
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, 80100 Via Sergio Pansini 5, Naples, Italy
    J Neurooncol 100:311-9. 2010
    ..Although treatment caused two episodes of grade 3-4 thrombocytopenia, a complete response and survival of more than three years were achieved, with a 30% increase in dose intensity compared with the standard fotemustine schedule...
  20. ncbi request reprint Management of gynaecomastia in patients with prostate cancer: a systematic review
    Giuseppe Di Lorenzo
    Department of Endocrinology and Molecular and Clinical Oncology, Second University Naples, Naples, Italy
    Lancet Oncol 6:972-9. 2005
    ..In this review, management options for gynaecomastia caused by hormonal manipulation in patients with prostate cancer are discussed...
  21. doi request reprint Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Cancer 116:1893-900. 2010
    ..The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette-Guérin (BCG) after BCG failure in high-risk, non-muscle-invasive bladder cancer (BC)...
  22. ncbi request reprint Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial
    Sisto Perdonà
    Department of Urology, National Tumour Institute, G Pascale Foundation IRCSS, Naples, Italy
    Lancet Oncol 6:295-300. 2005
    ..We aimed to compare tamoxifen with radiotherapy for prevention and treatment of gynaecomastia, breast pain, or both during bicalutamide monotherapy for prostate cancer...
  23. pmc Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml
    Matteo Ferro
    Urology Unit, University Federico II, Naples, Italy
    PLoS ONE 8:e67687. 2013
    ..001 and p = 0.01, respectively). In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA. ..
  24. doi request reprint Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading
    Daniela Terracciano
    Department of Cellular and Molecular Biology and Pathology L Califano, University of Naples Federico II, Naples, Italy
    Prostate 72:100-7. 2012
    ..To this aim an easy-available tool is represented by circulating biomarkers. Among these, the best candidates are some molecules involved in PCa pathogenesis such as IGFBP-2 and IGFBP-3, IL-6, and its soluble receptor (SIL-6R)...
  25. ncbi request reprint HER-2/neu receptor in prostate cancer development and progression to androgen independence
    Giuseppe Di Lorenzo
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Tumori 90:163-70. 2004
    ..Finally, clinical trials are in progress in prostate cancer patients to test novel agents that selectively interfere with HER-2/neu activity...
  26. ncbi request reprint Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial
    Marco De Sio
    Department of Urology, Seconda Universita di Napoli, Naples, Italy
    Urology 67:69-72. 2006
    ..To compare bipolar plasmakinetic (PK) with standard monopolar transurethral resection of the prostate (TURP)...
  27. ncbi request reprint The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?
    Riccardo Autorino
    Department of Urology, Second University, Naples, Italy
    Urol Res 33:460-4. 2005
    ..This selective alpha-blocker should therefore be included in the pharmacological regimen of patients when a conservative approach is considered in the treatment of ureteral lithiasis...
  28. ncbi request reprint Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Cancer 112:1147-52. 2008
    ..The current retrospective study investigated the activity and toxicity of PLD in pretreated patients with aggressive, nonvisceral CKS...
  29. doi request reprint Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection
    Sisto Perdonà
    Urology Section, Istituto Nazionale Tumori, Fondazione G Pascale, Naples, Italy
    Urol Oncol 31:761-5. 2013
    ..The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP)...
  30. doi request reprint Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms
    Matteo Ferro
    Department of Urology, University Federico II, Naples, Italy
    Oncol Rep 27:409-15. 2012
    ..In conclusion, in the human bladder cancer cell line HT-1376 pharmacological combination of CS with GEM or MMC resulted in a strong synergism on cell growth inhibition...
  31. doi request reprint An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples
    Giuseppe Di Lorenzo
    University Federico II of Napoli, Medical Oncology, Endocrinology and Oncology Department, Naples, Italy
    Expert Opin Pharmacother 12:1491-7. 2011
    ..To date, no trial data exist comparing treatment outcomes for everolimus versus sorafenib. The current analysis indirectly compares the overall survival (OS) benefit of everolimus and sorafenib as second-line treatment options...
  32. doi request reprint Immunotherapy for the treatment of prostate cancer
    Giuseppe Di Lorenzo
    Department of Endocrinology and Medical Oncology, Genitourinary Cancer Section, University Federico II, Via Pansini 5, Naples, Italy
    Nat Rev Clin Oncol 8:551-61. 2011
    ..We present the clinical developments in the field of immunotherapy and critically analyze methodological issues related to the evaluation of tumor responses to immunotherapy, trial design, and surrogate end points...
  33. ncbi request reprint Vesicourethral anastomosis during radical retropubic prostatectomy: does the number of sutures matter?
    Luigi Gallo
    Department of Urology, National Cancer Institute Pascale Foundation, Naples, Italy
    Urology 69:547-51. 2007
    ..To prospectively evaluate the outcome of radical retropubic prostatectomy using three different techniques of vesicourethral anastomosis (VUA), with a different number of sutures used during this surgical step...
  34. doi request reprint BAG3 protein delocalisation in prostate carcinoma
    Stefania Staibano
    Department of Biomorphological and Functional Sciences, Pathology Section, University Federico II of Naples, School of Medicine, Via S Pansini, 5, 80131, Naples, Italy
    Tumour Biol 31:461-9. 2010
    ..These results indicate that BAG3 intra-cytoplasmic delocalisation is a specific feature of cancer versus non-neoplastic prostate and a candidate new marker for prediction of prostate cancer invasiveness and behaviour...
  35. ncbi request reprint Update on PEG-interferon α-2b as adjuvant therapy in melanoma
    Rossella Di Trolio
    Unit of Medical Oncology and Innovative Therapy, G Pascale Institute of National Tumor Foundation, Naples, Italy
    Anticancer Res 32:3901-9. 2012
    ..This review, after a short summary of interferon α-2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease...
  36. ncbi request reprint Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma
    Marco De Sio
    Clinica Urologica, Seconda Universita degli Studi, Naples, Italy
    Urol Int 71:361-7. 2003
    ..We evaluated the characteristics of adrenal involvement and the accuracy of computerized tomography (CT) in the diagnosis of RCC, defining the real need for adrenalectomy during surgical treatment...
  37. doi request reprint Targeted therapy in the treatment of metastatic renal cell cancer
    Giuseppe Di Lorenzo
    Medical Oncology, University Federico II, Naples, Italy
    Oncology 77:122-31. 2009
    ..Immunotherapy confers a small but significant OS advantage but only for the minority of patients with good prognostic features. The results of these trials and ongoing efforts to improve treatment of MRCC are the focus of this review...
  38. pmc Efficacy of rituximab in gastric diffuse large B cell lymphoma patients
    Davide Leopardo
    Department of Endocrinology and Clinical Oncology, University Federico II, 80131, Naples, Italy
    World J Gastroenterol 16:2526-30. 2010
    ..To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL)...
  39. doi request reprint Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor
    Roberto Moretto
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples School of Medicine, Division of Medical Oncology, Naples, Italy
    Anticancer Drugs 24:759-64. 2013
    ..Furthermore, the thymus is rarely affected by metastases. To our knowledge, the present report is the first case of breast cancer metastatic to thymic epithelial tumor. ..
  40. doi request reprint Update on classic Kaposi sarcoma therapy: new look at an old disease
    Giuseppe Di Lorenzo
    Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy
    Crit Rev Oncol Hematol 68:242-9. 2008
    ..Among chemotherapeutic agents, recent data are offered from current trials that have focused on the role of pegylated liposomal doxorubicin as first- and second-line therapy...
  41. ncbi request reprint Expression of HECA-452 antigen correlates with disease relapse in mycosis fungoides
    Rossella Di Trolio
    Dermatology Section, Department of Systematic Pathology, University of Naples, Federico II, Naples, Italy
    Anal Quant Cytol Histol 30:203-8. 2008
    ..To determine the expression of HECA-452 epitope in mycosis fungoides (MF), assess whether its expression increases in relapsed MF compared with nonrelapsed MF and determine the potential prognostic relevance of HECA-452 expression...
  42. doi request reprint Imatinib mesylate in thymic epithelial malignancies
    Giovannella Palmieri
    Molecular and Clinical Endocrinology and Oncology Department, University Federico II, Via Pansini 5, 80128 Naples, Italy
    Cancer Chemother Pharmacol 69:309-15. 2012
    ....
  43. ncbi request reprint Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease
    Giuseppe Di Lorenzo
    Department of Oncology, Federico II University, Naples, Italy
    Tumori 89:349-60. 2003
    ..In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed...
  44. ncbi request reprint Management of AIDS-related Kaposi's sarcoma
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology and Oncology, University of Federico II, Naples, Italy
    Lancet Oncol 8:167-76. 2007
    ....
  45. doi request reprint Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung
    Carlo Buonerba
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via Sergio Pansini 5, Naples, Italy
    Anticancer Drugs 21:465-8. 2010
    ..Clinical investigations, conducted in large samples of patients, are necessary to evaluate the effectiveness of such an approach...